Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), its ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), including nivolumab, atezolizumab, and ipilimumab etc., have been increasingly applied in treating several kinds of cancers because of their evident efficacy [1, 2]. The gene discussed is CTLA4; the disease is cancer.